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Abstract  
In spite of their relative rarity, inheritable arrhythmias have come to the forefront as a group 
of potentially fatal  but preventable cause of sudden cardiac death in children and (young) 
adults. Comprehensive management of inherited arrhythmias includes diagnosing and treating 
the proband and identifying and protecting affected family members.  This has been made 
possible by the vast advances in the field of molecular biology enabling better understanding 
of the genetic underpinnings of some of these disease groups, namely congenital  long QT 
syndrome,  catecholaminergic  polymorphic  ventricular  tachycardia  and Brugada  syndrome. 
The ensuing knowledge of the genotype-phenotype correlations  enables us to risk-stratify, 
prognosticate and treat based on the genetic test results. The various diagnostic modalities 
currently available to us, including clinical tools and genetic technologies, have to be applied 
judiciously in order to promptly identify those affected and to spare the emotional burden of a 
potentially  lethal  disease in  the unaffected  individuals.  The therapeutic  armamentarium of 
inherited  arrhythmias  includes  pharmacological  agents,  device  therapies  and  surgical 
interventions. A treatment strategy keeping in mind the risk profile of the patients, the local 
availability of drugs and the expertise of the treating personnel is proving effective. While 
opportunities  for research are numerous in  this  expanding field of medicine,  there is  also 
tremendous scope for incorporating the emerging trends in managing patients and families 
with inherited arrhythmias in the Indian subcontinent.                                             
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Introduction
Inherited arrhythmias or cardiac channelopathies are primary electrical diseases of the heart 
characterized  by  dysfunctional  ion  channels  which  in  turn  lead  to  a  spectrum of  clinical 
manifestations ranging from complete lack of symptoms to life-threatening arrhythmias and 
sudden cardiac death (SCD) as the first symptom. In spite of their relative rarity they have 
come to the forefront as a group of potentially fatal but preventable cause of SCD in children 
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and  (young)  adults.                                          
Congenital long QT syndrome (LQTS) is the inherited arrhythmia syndrome that has been 
studied in  detail  and whose genotype-phenotype correlations  have largely been unraveled. 
Brugada syndrome (BrS) and catecholaminergic polymorphic ventricular tachycardia (CPVT) 
are  currently  intensively  studied  and  the  rarer  entities  like  short  QT  syndrome,  early 
repolarization syndrome, familial atrial fibrillation, premature cardiac conduction disease and 
idiopathic ventricular fibrillation are still largely under the surface. [1] The latter is mainly 
due to the rarity of these diseases precluding sufficient patient numbers to draw meaningful 
conclusions.
The mode of inheritance is predominantly autosomal dominant; however, autosomal recessive 
and sporadic mutations, which subsequently transmit as an autosomal dominant trait, are not 
uncommon.  Comprehensive management  of inherited arrhythmias includes diagnosing and 
treating the proband and identifying and protecting affected family members. [2] It has been 
shown that this can be achieved effectively with 70-80% of presymptomatically tested family 
members, after a couple of years of follow-up on treatment. [3] This review aims to throw 
some light on the emerging trends and their clinical applicability in managing individuals and 
families with inherited arrhythmia syndromes, highlighting the focus areas for cardiogenetics 
in  the  Indian  subcontinent.                                                
Diagnostic  evolution                                    
Our  understanding  of  genetic  causation,  of  the  correlation  between  dysfunctional  mutant 
genes and clinical manifestations, and of the various factors that influence disease expression 
has grown in leaps and bounds in the last couple of decades.                                  
Understanding the genetic  underpinnings                                             
The diagnosis of inherited arrhythmias has evolved mirroring the advances in the field of 
human genetics and genomics itself.  [4] The hundreds of genetic  aberrations that we now 
associate with this group of diseases is staggering; especially considering the fact that it was 
not long ago that the first causative genes for LQTS were discovered. [5] It is also interesting 
to note how the gap between basic and clinical science, or in other words between geneticists, 
primary  care  physicians  and  electrophysiologists,  seems  to  close  rapidly  and  an 
interdisciplinary team approach to patient care has emerged in this field of cardiology. [2]       
Today, not only are medical professionals more aware and increasingly efficient in picking up 
the individual and familial manifestations of these diseases, but are also better equipped with 
the diagnostic  and therapeutic  armamentarium necessary to  confirm clinical  suspicion and 
deploy  appropriate  treatment.  The  timely  and  adequate  management  of  affected  patients 
consists of two arms; firstly, a high level of suspicion and clinical astuteness to recognize the 
phenotype in an individual who may initially present to the emergency care team or to any 
other  medical  specialty,  and  secondly,  a  well-coordinated  cardiogenetic  team  to  provide 
genetic counseling and testing, to interpret the genetic data and to carry out family screening, 
and to make individualized therapeutic and follow-up decisions. [6,7]                                     
In a young patient presenting with the classical textbook features of an inherited arrhythmia 
syndrome, there is not much diagnostic ambiguity. For instance, aborted sudden cardiac arrest 
and prolonged heart rate corrected QT (QTc) interval in a previously healthy child with a 
family history of young sudden unexplained death is a clear indication of an underlying LQTS 
that  can  be  confirmed  by  targeted  genetic  testing.  However,  knowing  that  incomplete 
penetrance is  the rule rather than the exception in these diseases and that phenotypic and 
genetic variability are frequently encountered, next generation sequencing (NGS) techniques 
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now have a widespread role in detecting causative mutations when unsure of the underlying 
disease entity and in cases of SCD where corroborative clinical evidence is unavailable. The 
identification  of  a  disease-causing  gene  in  the  proband  then  paves  the  way  for  cascade 
screening  which  is  nothing  but  cardiovascular  assessment,  targeted  genetic  testing  and 
presymptomatic  treatment  of  at-risk  family  members.  [8]                          
Reinforcing  sound  clinical  knowledge                                         
In the different disease entities the molecular analysis can be done in a targeted way, although 
current methods allow for a more unbiased approach. Yet, detailed knowledge of genotype-
phenotype relationships is fundamental to the interpretation of the molecular genetic findings 
and the eventual therapeutic decisions to be taken. LQTS, as pointed out earlier, is the disease 
entity with the most clearly established genotype-phenotype relationship.  Indeed, based on 
various aspects of the clinical history of the proband and his or her family members and based 
on the ECG features the underlying genotype can be predicted with significant certainty. [9] 
This holds in particular for the most prevalent LQTS, i.e. LQTS types 1, 2 and 3. Patients with 
LQT1 typically present with symptoms during exercise, whereas LQT2 patients have their 
symptoms triggered by emotion or startle (like an alarm clock). [10] In the other primary 
arrhythmia syndromes genotype-phenotype relationships are less clear, but this relates mainly 
to the fact that large cohorts with a diverse underlying genotype are generally not available.
In spite of the myriad diagnostic advantages of genetic testing, the ECG remains a classical 
but practical diagnostic and risk stratifying tool in the clinical setting. Two recent studies on 
exercise testing have implied that the QT interval during the recovery phase (3-4 minutes) 
may reveal  a  diagnostic  QT prolongation  in  LQTS cases  with borderline  QTc interval  at 
baseline, as depicted in Figure 1.  [11,12]
Figure 1: ECGs of an exercise test in a 13-year old female with LQT1 (on beta-blocker therapy) are shown. QTc 
interval prolonged from 453ms (HR 85bpm) pre exercise (A) to 528ms (HR 95 bpm) 3 minutes post exercise 
(B). ECG=electrocardiogram; LQT1=long QT syndrome type1; QTc=corrected QT interval (Bazett's formula). 
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Further, postural changes from a supine position to standing may trigger a greater degree of 
QT prolongation in LQTS compared with controls and may eventually lead to the diagnosis of 
LQTS. [13] Figure 2 portrays these changes in QTc with posture. 
Figure 2: QT prolongation provoked during a lying-standing test in a 30-year old female with LQT1 (without 
medication). QTc was 493ms (HR 55bpm) at baseline in supine position (A). QTc prolonged to 541ms (HR 77 
bpm)  upon  standing  (B).                                    
These tests maybe particularly useful in borderline cases, but it has to be emphasized that 
prospective studies lack at this point in time. In both LQTS and BrS, drugs may give rise to a 
diagnostic ECG (and successive arrhythmic events), as is shown with the infusion of ajmaline 
in Figure 3. 
Figure 3: Typical type1 BrS ECG after intravenous ajmaline infusion. With ajmaline, coved-type ST elevation 
of >2mm and prolongation of PR interval is observed. The ECG was recorded from lead V1 and V2 from 2nd  
intercostal  space.                                          
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Such drugs are not limited to antiarrhythmic agents alone but also include psychotropic drugs, 
anesthetics  and  some  other  substances.  [14]  Currently,  healthcare  providers  can  access 
websites which list an increasing number of drugs to be avoided in patients with LQTS and 
BrS  (www.QTdrugs.org;  www.brugadadrugs.org).                          
Because  the  underlying  genetic  substrate  facilitates  the  diagnosis  (in  particular  in  family 
members) and impacts prognosis and therapeutic decisions, genetic testing in most of these 
syndromes  is  currently  regarded  a  mandatory  diagnostic  procedure  (i.e.  a  class  1 
recommendation). [15] The yield of molecular genetic testing depends on the disease under 
scrutiny and varies from 50-60% in LQTS (≥90% in LQTS families) to 20-30% in Brugada 
syndrome. [6,15] Further, it is important to be aware that location and coding type of mutation 
affect the risk profile. For example, in LQT1, individuals with a missense mutation in the 
transmembrane  portion  (especially,  a  cytoplasmic  loop)  carry  an  increased  risk  of  life-
threatening cardiac events; [16]  and in LQT2, males with a pore-loop (missense) mutation 
have a higher chance of life-threatening cardiac events whereas females have a high risk of 
life-threatening  events  regardless  of  the  mutation  location.  [17]                    
Going  beyond  the  causal  mutation                                             
As indicated, many of the diseases at stake are monogenic, i.e. one pathogenic variant in a 
gene  is  fully  responsible  for  the  phenotype.  Yet,  from the  very  first  description  of  large 
families it was obvious that there are remarkable differences in disease expression even within 
the same family. Several factors play a role in explaining these differences, including gender, 
age, and drug use. However, in recent years it has become more and more clear that there are 
important modifying genetic factors. [18] In LQTS some of these factors have been identified, 
with NOS1AP as the most important example. [19,20] Also, genetic factors impacting on the 
expression of the protein (either via the normal allele or the abnormal allele) significantly 
impact  on the severity of the phenotype,  as has been shown in LQT1. [21] Occasionally, 
patients do harbor more than one pathogenic mutations and not surprisingly these patients are 
typically more severely affected. [22] We do expect that in the years to come the identification 
of these genetic modifiers will modify risk stratification schemes in LQTS as is already the 
case  when  there  are  two pathogenic  mutations.                                      
Brugada syndrome has always been regarded a monogenic disease but recent data point to the 
fact that it might actually be an oligogenetic disease, i.e. based on a variety of gene variants, 
each of them with a smaller effect size compared to a pathogenic variant, but in combination 
sufficient to cause the full-blown phenotype. [23] Whether the presence of more variants also 
impact  on prognosis remains to be determined.  It  is interesting to note that  genome wide 
association  study  (GWAS),  an  approach  that  involves  rapidly  scanning  markers  across 
genomes of many individuals to find genetic variations associated with a particular disease, is 
throwing light on the new candidate genes that play a part in disease expression and severity. 
A very recent GWAS study involving 100,000 individuals from over 150 centers worldwide 
has identified 35 common variant loci associated with QT interval that collectively explain ~ 
8-10%  of  QT  interval  variation  and  highlight  the  importance  of  calcium  regulation  in 
myocardial  repolarization.  [24]                                        
Broadening  the  application  of  genetic  tests                                  
Several studies in the last  decade have helped reveal the genetic abnormalities underlying 
SCD and sudden infant deaths following which molecular autopsy or the genetic testing of 
deceased individuals has become integral in the diagnostic evaluation of families bereaving 
the  sudden death  of  a  close  relative.  [25]                                             
The use of NGS strategies (extended panels or even whole exome sequencing) has increased 
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the yield of pathogenic mutations but at the same time has also dramatically increased the 
yield of variants of uncertain significance. While significant research is underway in the area 
of  familial  cardiomyopathies  in  South  Asians  in  India,  [26]  there  are  but  a  handful  of 
publications describing inherited arrhythmias in this ethnically diverse population. 27,28] A 
concerted effort across the nation to gather existing data, plug the gaps in clinical evaluation 
and proceed with genetic counseling and testing is the way forward in this era where research-
based as well as commercial genotyping opportunities with sound bioinformatics backing are 
currently  more  readily  available.  [29]                                  
Therapeutic  advances                                       
Treatment options for inherited arrhythmias include lifestyle modifications, pharmacological 
agents, device therapy and surgical interventions. The recent consensus statement by Priori et 
al  provides  a lucid approach to risk-stratification  and choice of treatment  modality  in the 
different  arrhythmia  syndromes.  [2]  However,  a  case-based  rather  than  a  disease-based 
strategy is emerging as the key factor in the successful management of affected patients and 
families.  
Managing patients with drugs as first line therapy                                       
Beta-blockers, sodium channel blockers and a few other antiarrhythmic agents have proven to 
be of value in preventing arrhythmias of channelopathic origin. The role of beta-blockers, a 
globally available and cost-effective group of drugs, cannot be underestimated when dealing 
with adrenergic mediated primary arrhythmias such as LQT1, LQT2 and CPVT. The choice 
of beta-blocker should be based on history of cardiac events, type of LQTS, age of the patient, 
comorbidities  and local  availability  of drugs.  [30,31] While  nadolol,  a non-selective  beta-
blocker with unique pharmacodynamic and pharmacokinetic properties, has better arrhythmia 
suppressing ability compared to the other beta-blockers, it's use is often limited by its lack of 
availability. [32] On the same note, quinidine, the singular antiarrhythmic agent useful in BrS 
and idiopathic ventricular fibrillation, is unavailable in most parts of the world which warrants 
the immediate attention of policymakers. [33] For LQTS, new drugs targeting the late sodium 
inward current are on the way. [34] Acute administration of ranolazine has been tested already 
in small LQT3 patient cohorts. [35] However, long-term studies with these drugs are awaited. 
In CPVT, flecainide has recently shown to be quite effective in suppressing arrhythmia burden 
both experimentally and clinically (Figure 4). [36] In clinical studies, flecainide was used in 
addition to beta-blocker therapy (plus verapamil in some cases). 
Choosing  appropriate  adjuvant  therapies                              
Implantable  cardioverter  defibrillator  (ICD)  is  an  arrhythmia-aborter  for  ventricular 
arrhythmias that may spiral to lethal proportions and is therefore an integral part of managing 
high-risk  channelopathic  patients.  The  high  complication  rate  and  the  excessive  cost 
associated with this choice of therapy are major disadvantages, thus once again precluding its 
uniform utilization globally. Having said so, weighing the pros and cons of the device versus 
the risk of SCD is the only way out of the therapeutic dilemma of whether or not to implant 
one in young patients and their family members. [37,38] It has to be highlighted that while 
technological  advances  have  lead  to  procedure-light  options  such  as  wearable  ICDs,  the 
healthcare inequalities are still so prevalent in low and middle income countries that reuse of 
ICDs has been tested and even shown to be successful. [39,40] In BrS with (multiple) ICD 
shocks due to recurrent ventricular fibrillation (VF), catheter ablation of epicardial arrhythmic 
substrates in the right ventricular outflow tract is a powerful adjunctive therapy to suppress 
arrhythmic  events.  [41]  Currently,  this  complex  procedure  is  reserved  only  for  severely 
affected  patients  with  recurrent  VF events  and only  centers  with  extensive  experience  in 
epicardial ablation with surgical backup should perform the procedure. [42]  
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Figure 4: ECGs during exercise testing before and after drug treatments in a 31-year old female with CVPT. At 
baseline before medication (A), NSVT and bouts of VES were observed. After metoprolol (100mg/day), frequent 
VES  still  appeared  during  the  test.  With  metoprolol  (100mg/day)  and  flecainide  (150mg/day),  ventricular 
arrhythmias were suppressed and only a few VES were recorded throughout the test. Notably, there is no QRS 
prolongation during exercise on flecainide therapy. ECG=electrocardiogram; NSVT=non-sustained ventricular 
tachycardia;  CPVT=catecholaminergic  polymorphic  ventricular  tachycardia;  VES=ventricular  extrasystoles.
Left cardiac sympathetic denervation (LCSD), which refers to surgical resection and removal 
of the lower part of the stellate ganglion and the upper fibers of the thoracic ganglia,  has 
become established as a neuromodulator in the management of therapy-resistant arrhythmias 
and recurrent ICD shocks. [43] A significant reduction in arrhythmia episodes was observed 
in Dutch LQTS and CPVT patients after LCSD, and LQT1 was more responsive than LQT2. 
[44] There appears to be a potential role for bilateral cardiac sympathetic denervation in the 
abolition of ventricular tachycardia storm and in treating refractory ventricular tachycardia but 
its  value  in  long-term care  warrants  exploration.  [45]                                 
Applying  the  emerging  trends  in  our  patients                                   
In the Indian context, there are both positives and negatives. While clinically diagnosed cases 
are being treated as per the international guidelines with some modifications based on local 
conditions, there is a need to educate healthcare professionals on identifying the red flag signs 
of underlying channelopathic diseases. Genetic counseling and genotyping are yet to become 
routine practice for even the well-established diseases like LQTS, and postmortem molecular 
diagnostics is non-existent. It is surprising to note that a detailed family history and pedigree 
chart, as critical as they are in proband evaluation, are not adequately documented in cases 
provisionally managed as inherited arrhythmias. With only a few tertiary referral hospitals 
using  electronic  health  records,  data  retrieval  of  suspected  cases  is  proving  tedious. 
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Nevertheless,  systematic,  coordinated  steps  are  underway  to  address  these  issues  at  a 
nationwide  level,  keeping  in  mind  the  success  stories  of  international  registries  and 
collaborative  teamwork in understanding and addressing the complex inherited arrhythmia 
disorders.  
Research  avenues                                        
Research  opportunities  abound in  this  rapidly  expanding field  of  medicine.  As diagnostic 
challenges  still  continue to daunt experts, newer avenues in stem cell  biology and genetic 
technologies, such as induced pluripotent stem cells and genome wide association studies, are 
potential answers to the various unsolved mysteries of ion channel diseases. [46,47] Research 
into fetal diagnosis and management of LQTS utilizing newer imaging modalities is proving 
promising. [48] While randomized trials are almost impossible in these rare and lethal disease 
entities,  observational  studies  and retrospective  analyses  of  large  databases  are  filling  the 
knowledge  gap.                                                  
Strong headways are also being made to expand the treatment  options with the relentless 
support of translational research groups and clinical research projects. Expanding the realms 
of existing therapeutic modalities, such as with highly evolved ICDs and increasingly precise 
denervation techniques, is the focus of experts at the present time. Recently, renal denervation 
and other neuromodulators have gained attention in the alteration of heart failure progression 
and  atrial  arrhythmogenesis,  and  might  have  potential  application  in  the  management  of 
channelopathies  as well.  [49] On another  note,  experimental  evidence is  accumulating  for 
microRNA-mediated  regulation  of  atrial  fibrillation,  and  they  appear  to  be  promising 
therapeutic  targets  for this  common arrhythmia.  [50] The fact  that  developing nations are 
investing resources in medical and basic science research is a very positive sign and young 
clinicians and scientists should make every attempt to develop their research skills with the 
broader  aim  of  advancing  patient  care.                                         
Concluding  remarks                                       
The diagnostic and therapeutic tools available with us today are to be applied judiciously to 
reduce  the  mortality  and  morbidity  due  to  undiagnosed  and  uncontrolled  inherited 
arrhythmias. While we are fortunate to be part of the ongoing genetic revolution, the sheer 
volumes of genetic  data churned out on a case per case basis also challenge us. There is 
probably  a  need  for  interdependency,  now  more  than  ever  before,  amongst  the  various 
specialists in a cardiogenetic team to fully understand the complex situation at hand, to gain 
the confidence of patients, to help them make informed decisions and to provide lifelong care 
and support for affected families. With information technology coming in pocket sizes and 
microchip shapes, being up-to-date with global trends in this field is not only crucial for our 
own personal  sakes  but  also  for  the  appropriate  counseling  of  young individuals  seeking 
evidence-based answers  to  questions  and dilemmas  relating  to  their  potentially  lethal  but 
treatable  medical  conditions.                                         
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